[Translation] Phase I clinical study on the safety, tolerability, pharmacokinetics and pharmacodynamics of HSK34890 tablets after repeated administration in patients with type 2 diabetes
主要目的:评价 HSK34890 片在 2 型糖尿病患者中给药 4 周的安全性和耐受性; 次要目的: 1. 评价 HSK34890 片在 2 型糖尿病患者中给药 4 周的药代动力学特征; 2. 评价 HSK34890 片在 2 型糖尿病患者中给药 4 周的药效动力学特征; 探索性目的:评价 HSK34890 片在 2 型糖尿病患者中的剂量效应关系;
[Translation] Primary objective: To evaluate the safety and tolerability of HSK34890 tablets in patients with type 2 diabetes after 4 weeks of administration. Secondary objectives: 1. To evaluate the pharmacokinetic characteristics of HSK34890 tablets in patients with type 2 diabetes after 4 weeks of administration. 2. To evaluate the pharmacodynamic characteristics of HSK34890 tablets in patients with type 2 diabetes after 4 weeks of administration. Exploratory objective: To evaluate the dose-effect relationship of HSK34890 tablets in patients with type 2 diabetes.